Your browser doesn't support javascript.
loading
Identification of metabolic signatures related to metastasis and immunotherapy resistance in oral squamous cell carcinoma.
Chen, Haoran; Liu, Xin; Yao, Feng; Yin, Miao; Cheng, Bo; Yang, Sisi.
Afiliação
  • Chen H; Department of Stomatology, Zhongnan Hospital of Wuhan University Wuhan, Hubei, China.
  • Liu X; Department of Immunology and National Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College Beijing, China.
  • Yao F; Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute Beijing, China.
  • Yin M; Department of Stomatology, Zhongnan Hospital of Wuhan University Wuhan, Hubei, China.
  • Cheng B; Department of Stomatology, Zhongnan Hospital of Wuhan University Wuhan, Hubei, China.
  • Yang S; Department of Stomatology, Zhongnan Hospital of Wuhan University Wuhan, Hubei, China.
Am J Transl Res ; 15(1): 373-391, 2023.
Article em En | MEDLINE | ID: mdl-36777871
ABSTRACT

OBJECTIVES:

In this study, we aimed to identify the metabolic genes associated with the metastasis and immunotherapy resistance of oral squamous cell carcinoma (OSCC) and to construct a metabolic gene-related predictive model for the prognosis of OSCC.

METHODS:

RNA-seq data were download from The Cancer Genome Atlas (TCGA). Weighted gene co-expression network analysis (WGCNA) was applied to identify the modules related to EMT, stemness, and checkpoint signatures in OSCC. Univariate Cox and the least absolute shrinkage and selection operator (LASSO) methods were used to construct the metabolic gene signature. Furthermore, the scRNA-seq data were obtained from Gene Expression Omnibus (GEO) database and analyzed using "Seurat" and "CopyKAT" packages.

RESULTS:

The risk prediction model was constructed using the 12 metabolic-related gene signature. Based on this model, risk score of each sample was calculated and used to divide the samples into low- and high-risk groups. Our model was effective as the risk score was significantly associated with clinical features and genetic mutations. Meanwhile, we found that lipid metabolism, glycolysis, amino acid metabolism, and drug metabolism differed between high- and low-risk groups. Pathways associated with malignant tumor and immunosuppression were enriched in high-risk group. Furthermore, low-risk group showed a more activated immune status and was predicted to have better response to immunotherapy. Finally, through single-cell transcriptome analysis, we assessed the expression of these 12 genes in tumor and non-tumor cells and verified the existence of two clusters of tumor cells with different degrees of malignancy at the cellular level.

CONCLUSIONS:

Our study demonstrates the clinical significance of metabolic related gene signature for the treatment of OSCC and suggests potential therapeutic targets and pathways for OSCC.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article